Patents by Inventor John N. Feder

John N. Feder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
    Patent number: 7312086
    Abstract: The present invention provides novel polynucleotides encoding HGPRBMY23 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY23 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly renal diseases and/or disorders, colon cancer, breast cancer, and diseases and disorders related to aberrant NFKB modulation. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: December 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Thomas C. Nelson, Chandra S. Ramanathan, Rolf-Peter Ryseck, Michael G. Neubauer
  • Antibodies directed to the testis-specific tubulin tyrosine-ligase-like protein, BGS42
    Patent number: 7309779
    Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: December 18, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee
  • Human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1
    Patent number: 7304141
    Abstract: The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel A. Mintier, David Bol
  • Metalloprotease highly expressed in the testis, MMP-29
    Patent number: 7285633
    Abstract: The present invention provides novel polynucleotides encoding MMP-29 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MMP-29 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: October 23, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shujian Wu, Jian Chen, John N. Feder, Liana Lee, Stanley R. Krystek
  • Polynucleotides encoding a novel human G-protein coupled receptor splice variant, HGPRBMY29SV2
    Patent number: 7276354
    Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: October 2, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel A. Mintier, David Bol
  • Method of diagnosing testicular tumors using polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42
    Patent number: 7273706
    Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: September 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee
  • Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
    Patent number: 7259002
    Abstract: The present invention provides novel polynucleotides encoding MGAT3 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing MGAT3 polypeptides, fragments, and homologues thereof. The invention further relates to diagnostic and therapeutic methods for applying these novel MGAT3 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, such as obesity. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: August 21, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Thomas C. Nelson, Jian Chen, Rupalie Meegalla, Michael Ramaker, Dong Cheng
  • Polynucleotide encoding a TRP channel family member, TRP-PLIK2
    Patent number: 7223557
    Abstract: The present invention provides novel polynucleotides encoding TRP-PLIK2 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of TRP-PLIK2 polypeptides, TRP-PLIK2b, TRP-PLIK2c, and TRP-PLIK2d, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel TRP-PLIK2, TRP-PLIK2b, TRP-PLIK2c, and TRP-PLIK2d polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Han Chang, Liana M. Le, Michael A. Blanar, David Bol
  • Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
    Patent number: 7223558
    Abstract: The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shujian Wu, Stanley R. Krystek, Liana Lee, John N. Feder, Janet D. Cheng
  • Acetyl CoA carboxylase 2 sequences and methods
    Patent number: 7211423
    Abstract: The present invention relates generally to novel nucleotide and amino acid sequences, and more particularly to novel human acetyl CoA carboxylase 2 (ACC2) and rat ACC2 sequences. The sequences provided herein can be expressed in a recombinant format. Methods of isolating the ACC2 sequence are also provided, which can be employed to isolate any ACC sequence. The ACC2 sequences can be employed in therapeutic applications to diagnose or treat a condition associated with ACC2. The invention also relates to the identification of modulators of ACC activity using the recombinant human ACC2 enzyme as the screening target.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: May 1, 2007
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Dong Cheng, John N. Feder, Luping Chen, Ching-Hsuen Chu
  • Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
    Patent number: 7202056
    Abstract: The present invention provides novel polynucleotides encoding BGS-19 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying the novel BGS-19 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: April 10, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liana M. Lee, John N. Feder, Shujian Wu, Jian Chen
  • Polynucleotides encoding human histone deacetylase HDAC9c
    Patent number: 7199227
    Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: April 3, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald G. Jackson, Matthew V. Lorenzi, Ricardo M. Attar, Marco Gottardis, Liana M. Lee, John N. Feder
  • Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1
    Patent number: 7189539
    Abstract: The present invention provides novel polynucleotides encoding HGPRBMY5v1 and HGPRBMY5v2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY5v1 and HGPRBMY5v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: March 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chandra S. Ramanathan, John N. Feder, Gabriel Mintier, Kelly L. Bennett
  • Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
    Patent number: 7183379
    Abstract: The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: February 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel A. Mintier
  • Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
    Patent number: 7153678
    Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 26, 2006
    Assignee: Bristol-Myers Squibb
    Inventors: Donald G. Jackson, Chandra S. Ramanathan, John N. Feder, Liana Lee, Thomas C. Nelson, Nathan Siemers, Suzanne J. Suchard, Joshua Finger, C. Gordon Todderud, Dana Banas
  • Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
    Patent number: 7141381
    Abstract: The present invention describes two newly discovered Human Leucine Rich Repeat (LRR)-containing proteins, HLRRNS-2 and HLRRNS-3, and their encoding polynucleotides. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotides and/or polypeptides of the present invention. In addition, methods involving the new HLRR-containing proteins HLRRNS-2 and HLRRNS-3, or modulators thereof, for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, neurological conditions, and diseases or disorders related to the brain are illustrated.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Gabriel Mintier, Chandra S. Ramanathan
  • Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
    Patent number: 7129085
    Abstract: The present invention provides novel polynucleotides encoding HLLRCR-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLLRCR-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly nervous system diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: October 31, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel Mintier
  • Testis-specific tubulin tyrosine-ligase-like protein, BGS42
    Patent number: 7122358
    Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: October 17, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Thomas C. Nelson, Shujian Wu
  • Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
    Patent number: 7119170
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: October 10, 2006
    Assignees: Bio-Rad Laboratories, Inc, California Institute of Technology
    Inventors: John N. Feder, Pamela J. Bjorkman, Randall C. Schatzman
  • Methods of diagnosing renal tumors by determining the expression level of RNA encoding the HGPRBMY18 polypeptide
    Patent number: 7115375
    Abstract: The present invention describes a newly discovered human G-protein coupled receptor and its encoding polynucleotide. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotide and/or polypeptide of the present invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, endocrine conditions, neurological conditions, and diseases or disorders related to the pituitary gland, colon, breast, lungs, kidney, and prostate are illustrated.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: October 3, 2006
    Assignee: Bristol-Myers Squibb
    Inventors: John N. Feder, Gabriel Mintier, Chandra S. Ramanathan